Century Therapeutics, Inc. develops induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. Its platform uses an iPSC cell foundry and Allo-Evasion™ immune-evasion engineering to create allogeneic beta islet, T cell and natural killer cell programs, including CNTY-813 for type 1 diabetes and CD19-targeted CAR-iT work such as CNTY-308.
Recurring company updates address preclinical data presentations, regulatory-pathway disclosures, financial results, investor presentations, board and committee changes, and collaboration economics tied to the company’s collaboration, option and license agreement with Bristol-Myers Squibb.
Century Therapeutics (NASDAQ: IPSC) reported its Q2 2022 results, ending June 30 with $429.4M in cash. The company is set to initiate the Phase 1 ELiPSE-1 trial for CNTY-101, pending FDA clearance, targeting relapsed/refractory CD19 positive lymphoma. Collaboration revenue stood at $1.4M, while R&D expenses rose to $24.5M due to expanded capabilities. General and administrative costs increased to $8.3M, leading to a net loss of $31M. The company forecasts 2022 operating expenses between $155M and $165M, with a cash runway extending into 2025.
Century Therapeutics (NASDAQ: IPSC) will join the Russell Microcap Index effective June 27, 2022, following the Russell indexes annual reconstitution. This membership lasts one year and includes automatic inclusion in corresponding growth and value style indexes. The Russell indexes are utilized by investment managers and institutional investors, with approximately $12 trillion in assets benchmarked against them. Century Therapeutics focuses on developing iPSC-derived cell therapies for cancer treatment, aiming to overcome limitations of existing therapies.
Century Therapeutics (NASDAQ: IPSC) will have its CEO, Lalo Flores, Ph.D., participate in a fireside chat at the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 28, 2022, at 9:30 AM ET. The event will discuss the company's innovative work in induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology. Interested parties can access a live webcast on the company’s website, with a replay available for 30 days.
Century Therapeutics (NASDAQ: IPSC) announced a virtual Research and Development Day on June 13, 2022, from 4:30 PM to 6:00 PM ET. The event will showcase presentations from the management team and Dr. Sheila Singh, focusing on next-generation iPSC-derived cell therapy technologies, particularly in treating glioblastoma with CNTY-103. This event aims to highlight the company's advancements in immuno-oncology and its innovative approach to addressing cancer therapies.
Century Therapeutics (NASDAQ: IPSC) reported its Q1 2022 financial results, highlighting a cash position of $466.4 million and a net cash provided by operations of $86.8 million. The company plans to initiate its Phase 1 ELiPSE-1 trial for CNTY-101 in relapsed/refractory lymphoma in H2 2022 after IND submission. R&D expenses increased to $21.2 million, driven by expanded headcount and studies. The net loss stood at $37.5 million. The company expects its financial resources to sustain operations through 2025.
Century Therapeutics (NASDAQ: IPSC) announced participation in key investor conferences in May 2022. The management team will engage in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on May 10 at 8:40 AM PT, and present at the H.C. Wainwright Global Investment Conference on May 24, available on-demand from 7:00 AM ET. Replays of these events will be accessible for 30 days on the Company’s website. Century focuses on iPSC-derived cell therapies for cancer treatment.
Century Therapeutics (NASDAQ: IPSC) announced that preclinical data on MAD7, a novel CRISPR nuclease enabling genetic engineering of iPSC-derived NK and T cell therapies, will be presented at the ASGCT 25th Annual Meeting from May 16-19, 2022, in Washington, D.C. The presentation will focus on enhancing iPSC-based cell therapies, with details including an abstract number of 952, scheduled for May 18, 2022, at 5:30 PM ET. The company aims to overcome limitations of first-generation cell therapies with its innovative approaches to cancer treatment.
On April 18, 2022, Century Therapeutics (NASDAQ: IPSC) announced that its management team will present at the virtual Chardan Genetic Medicines and Cell Therapy Manufacturing Summit on April 25, 2022, at 9:30 AM ET. A live webcast will be available on the company's website, and a replay will be archived for 30 days. The company specializes in developing iPSC-derived cell therapies to target hematologic and solid tumors, aiming to enhance patient access to cancer treatments.
Century Therapeutics (NASDAQ: IPSC) will have CEO Lalo Flores present at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 10:15 AM ET. He will also participate in a panel discussing key features in NK Cellular Therapeutics on April 14, 2022, at 11:00 AM ET. A live webcast of the presentation will be available on the company’s website, with an archived replay for 30 days post-event. Century Therapeutics focuses on developing innovative iPSC-derived cell therapies aimed at treating hematologic and solid tumor cancers.
Century Therapeutics (NASDAQ: IPSC) announced that CEO Lalo Flores, Ph.D., will present at the H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30, 2022. The presentation will focus on the company's development of induced pluripotent stem cell (iPSC)-derived cell therapies aimed at treating cancer. A recording will be available on their website starting March 30 at 7:00 AM ET for 90 days. Century's innovative approach seeks to advance cancer care by leveraging adult stem cells and genetic engineering.